Buerger’s Disease Market to Surge Owing to Stem Cell Therapy Growth

Buerger’s Disease Market to Surge Owing to Stem Cell Therapy Growth

Buerger’s disease, or thromboangiitis obliterans, is a rare vascular disorder characterized by inflammation and thrombosis in small- and medium-sized arteries and veins of the extremities. The market offers a spectrum of therapeutic products—from anticoagulants and vasodilators such as prostaglandin analogs that improve blood flow and reduce ischemic pain, to smoking cessation aids that address the primary risk factor.

Emerging regenerative solutions, including mesenchymal stem cell therapies and gene-based interventions, aim to repair vascular damage and modulate inflammatory pathways for long-term remission. These advanced treatments promise higher limb salvage rates and enhanced quality of life compared to conventional pharmacotherapy. With growing patient awareness, favorable reimbursement policies and robust R&D activity targeting vascular regeneration, demand for innovative, minimally invasive options is on the rise.

According to CoherentMI, The Buerger's disease market is estimated to be valued at USD 443.7 million in 2025 and is expected to reach USD 641.2 million by 2032, growing at a compound annual growth rate (CAGR) of 5.4% from 2025 to 2032.

Key Takeaways

Key players operating in the Buerger’s Disease Market are:

-AnGes Inc.

-Mitsubishi Tanabe Pharma Corporation

-Pluristem Therapeutics Inc.

-Stempeutics Research Pvt. Ltd.

-Fuji Yakuhin Co., Ltd.

These companies are driving growth through strategic collaborations, licensing agreements and investment in clinical trials for novel vascular repair technologies.

The Buerger’s Disease Market is witnessing rising demand as smoking prevalence remains high in certain regions and incidence of peripheral arterial disorders escalates. Increased diagnostic screening, growing geriatric populations and heightened government initiatives for rare diseases are further fueling the need for targeted therapies and patient support programs.

Technological advancements are reshaping the competitive landscape. Innovations include 3D-printed vascular scaffolds, AI-powered imaging tools for early detection and regenerative cell platforms harnessing autologous stem cells. These developments not only improve treatment efficacy but also reduce hospitalization times and overall healthcare costs.

Market Trends
One key trend is the accelerated adoption of regenerative medicine. Stem cell–based therapies and gene editing tools are progressing through later-stage trials, offering durable vascular repair and immune modulation. This shift from symptomatic management to disease modification is redefining treatment protocols and reimbursement frameworks.
A second trend is the integration of digital health solutions. Wearable sensors and telemonitoring platforms enable real-time tracking of limb perfusion and wound healing. Such remote monitoring reduces clinic visits, lowers patient burden and provides actionable data for personalized treatment adjustments, driving higher patient engagement and better outcomes.

Market Opportunities

One major opportunity lies in emerging economies of Asia-Pacific and Latin America, where smoking rates are high and healthcare infrastructure is rapidly modernizing. Market entrants can leverage partnerships with local distributors and invest in awareness campaigns to expand penetration. Improved reimbursement policies in these regions further support product uptake.
Another opportunity stems from the robust pipeline of gene therapies and cell-based products. Upcoming approvals for targeted gene modulation agents and off-the-shelf stem cell formulations are expected to open new revenue streams. Companies focusing on regulatory alignment and scalable manufacturing can capture first-mover advantages and establish long-term market leadership.

Impact of COVID-19 on Buerger’s Disease Market Growth

Prior to the global pandemic, the Buerger’s disease treatment landscape was characterized by steady clinical trial activity, incremental innovation in cell-based therapies and a growing emphasis on lifestyle-modification programs. Patient recruitment for observational studies and interventional trials proceeded at a moderate pace, while treatment centers focused on refining surgical interventions and adjunctive pharmacotherapies. Distribution channels for specialized prostaglandin analogs and regenerative approaches were largely stable, supported by in-person consultations and outpatient visits. Awareness campaigns and physician education initiatives helped maintain consistent adoption rates across major treatment hubs.

During the pandemic’s early months, lockdown measures and resource reallocation disrupted routine care pathways. Elective procedures were postponed and research centers pivoted their focus to infectious-disease priorities. Many patients with Buerger’s disease experienced delays in diagnosis and treatment escalation, further complicated by reduced access to vascular imaging and limited availability of rehabilitation services. Supply-chain constraints affected timely delivery of advanced regenerative products, while staffing shortages in vascular clinics led to prolonged wait times. Virtual consultations emerged as a temporary workaround, but full replacement of hands-on diagnostic assessments remained challenging.

In the medium term, post-pandemic recovery has seen clinics and research institutions implement hybrid models of care. Telehealth platforms now coexist with in-person visits, improving continuity for patients under long-term surveillance. Investigational protocols have been redesigned to include remote monitoring of limb perfusion and patient-reported outcomes. Moreover, regulatory bodies have provided guidance for decentralized trial conduct and expedited review of therapies addressing critical unmet needs in chronic vascular conditions. Manufacturers have reinforced supply chains by qualifying multiple logistics partners and adopting digital tracking systems to prevent future disruptions.

Looking ahead, strategies should emphasize resilience through diversified trial sites, integration of digital health tools and strengthened collaboration with patient advocacy groups. Embracing adaptive study designs and real-world data collection will reduce dependency on traditional clinic-centric models. Supply-chain risk management must include onshore manufacturing options and just-in-case inventory buffers. Finally, targeted outreach to underserved communities—leveraging mobile health units and community health workers—will ensure patients with Buerger’s disease maintain access to timely diagnostics and advanced therapeutics, regardless of external public-health pressures.

Geographical Regions with Highest Market Value Concentration

North America has traditionally commanded a significant share of the Buerger’s disease market, driven by advanced healthcare infrastructure and high per-capita healthcare spending. Specialized vascular centers in the United States and Canada concentrate expertise in limb salvage and regenerative therapies. Well-established reimbursement pathways for prostaglandin analogs and cell-based interventions facilitate wider adoption, while academic medical centers spearhead many pivotal clinical trials. Awareness campaigns funded by national health agencies and patient advocacy networks further reinforce the region’s leadership in both diagnosis and management of Buerger’s disease.

In Europe, Western European countries such as Germany, France and the United Kingdom represent another core value cluster. National health systems with universal coverage ensure broad access to diagnostic angiography and microsurgical revascularization procedures. Collaborative research consortia across the European Union drive harmonized protocols for cell therapy applications and standardized patient-reported outcome measures. Centralized procurement mechanisms and cross-border healthcare directives also contribute to consistent market uptake of emerging therapeutic modalities, particularly in Scandinavia where public health programs monitor smoking cessation as a key preventative strategy.

East Asia stands out as a third focal region, led by Japan and South Korea. A strong emphasis on regenerative medicine research and government incentives for biotech innovation underpin market strength. National health insurance schemes in these countries cover a range of advanced treatments, including cell therapies for vascular diseases, creating a supportive environment for product launches. Clinical networks between metropolitan research hospitals and regional centers ensure rapid patient enrollment in studies, further reinforcing the market’s value concentration.

To a lesser extent, select countries in the Middle East and Latin America contribute through targeted specialty clinics within major urban hubs. While overall volumes may be smaller, these centers often serve as regional referral points and test beds for novel therapeutic approaches, complementing the larger markets in North America, Europe and East Asia.

Fastest-Growing Region for the Buerger’s Disease Market

The Asia-Pacific region has emerged as the fastest-growing market for Buerger’s disease therapies, propelled by a combination of epidemiological shifts, expanding healthcare infrastructure and supportive regulatory reforms. Rising awareness of tobacco-associated vascular pathology, coupled with surging demand for advanced medical interventions, has spurred significant investments in specialized vascular clinics. Countries such as India, China and Australia are witnessing rapid establishment of multidisciplinary centers offering both surgical and regenerative treatment options, meeting a previously unmet need for comprehensive care.

China’s regulatory authority has introduced accelerated pathways for innovative biologics and cell therapies targeting chronic vascular conditions, reducing approval timelines and encouraging local biotech development. Simultaneously, tier-two and tier-three cities are upgrading diagnostic capabilities by acquiring high-resolution imaging equipment and training vascular specialists, broadening the patient pool beyond major metropolitan centers. Public-private partnerships finance mobile clinics and televascular services, enabling remote evaluations and early intervention in rural areas.

In India, government initiatives to control tobacco use are complemented by expansion of tertiary care hospitals with dedicated vascular surgery and interventional radiology departments. Philanthropic organizations and health ministries collaborate to provide subsidized treatment for low-income patients, stimulating demand for effective, cost-efficient therapies. Local manufacturing of key regenerative products has expanded, reducing dependency on imports and lowering treatment costs.

Australia and New Zealand leverage strong research-hospital linkages to accelerate adoption of emerging cell-based treatments, integrating them into national cardiovascular strategy plans. Regulatory support for compassionate use programs allows access to novel therapies ahead of formal market launch, further driving growth. Clinical registries capturing patient outcomes in these countries enable continuous improvement and real-world evidence generation, reinforcing confidence among healthcare professionals and payers.

Across Asia-Pacific, digital health platforms facilitate patient education, post-treatment monitoring and adherence to smoking cessation protocols—key factors in improving long-term outcomes and sustaining market momentum. These combined drivers solidify the region’s position as the fastest-growing landscape for Buerger’s disease management.

‣ Get More Insights On: Buerger’s Disease Market

‣ Get this Report in Japanese Language: バージャー病市場

‣ Get this Report in Korean Language: 버거병시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)